|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
2,250,000,000 |
Market
Cap: |
93.44(B) |
Last
Volume: |
20,542,542 |
Avg
Vol: |
12,077,193 |
52
Week Range: |
$40.25 - $64.73 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
|
S&P 100 |
|
S&P 500 |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 97 |
Guru Rank Value : 8.6 |
Guru Occurances : 3 |
|
|
|
|
|
|
|
Company Profile Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
13,571 |
13,571 |
Total Buy Value |
$0 |
$0 |
$672,994 |
$672,994 |
Total People Bought |
0 |
0 |
2 |
2 |
Total Buy Transactions |
0 |
0 |
3 |
3 |
Total Shares Sold |
0 |
0 |
18,718 |
616,397 |
Total Sell Value |
$0 |
$0 |
$1,146,397 |
$44,859,834 |
Total People Sold |
0 |
0 |
2 |
5 |
Total Sell Transactions |
0 |
0 |
2 |
11 |
End Date |
2024-03-31 |
2023-12-29 |
2023-06-30 |
2022-06-30 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Andreotti Lamberto |
Director |
|
2016-11-01 |
4 |
OE |
$22.14 |
$6,772,825 |
D/D |
305,909 |
998,777 |
|
- |
|
Bancroft Charles A |
EVP & Chief Financial Officer |
|
2016-11-01 |
4 |
D |
$50.80 |
$70,917 |
D/D |
(1,396) |
186,398 |
|
- |
|
Bancroft Charles A |
EVP & Chief Financial Officer |
|
2016-11-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,100 |
187,794 |
|
- |
|
Andreotti Lamberto |
Director |
|
2016-10-11 |
4 |
OE |
$17.51 |
$6,456,042 |
D/D |
368,706 |
692,868 |
|
- |
|
Andreotti Lamberto |
Director |
|
2016-09-30 |
4 |
A |
$53.92 |
$24,965 |
D/D |
463 |
324,162 |
|
- |
|
Andreotti Lamberto |
Director |
|
2016-09-08 |
4 |
AS |
$56.97 |
$615,276 |
D/D |
(10,800) |
323,699 |
|
- |
|
Andreotti Lamberto |
Director |
|
2016-09-07 |
4 |
AS |
$56.77 |
$613,116 |
D/D |
(10,800) |
334,499 |
|
- |
|
Nielsen Anne |
Chief Compliance & Ethics Off |
|
2016-09-03 |
4 |
D |
$56.96 |
$48,359 |
D/D |
(849) |
28,873 |
|
- |
|
Nielsen Anne |
Chief Compliance & Ethics Off |
|
2016-09-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,596 |
29,722 |
|
- |
|
Andreotti Lamberto |
Director |
|
2016-08-25 |
4 |
AS |
$58.92 |
$683,472 |
D/D |
(11,600) |
345,299 |
|
- |
|
Andreotti Lamberto |
Director |
|
2016-08-24 |
4 |
AS |
$58.82 |
$689,359 |
D/D |
(11,600) |
356,899 |
|
- |
|
Gordon Murdo |
EVP, Chief Commercial Officer |
|
2016-08-01 |
4 |
D |
$76.19 |
$59,733 |
D/D |
(784) |
14,466 |
|
- |
|
Gordon Murdo |
EVP, Chief Commercial Officer |
|
2016-08-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,511 |
15,250 |
|
- |
|
Andreotti Lamberto |
Director |
|
2016-07-08 |
4 |
AS |
$74.74 |
$870,461 |
D/D |
(11,600) |
368,499 |
|
- |
|
Andreotti Lamberto |
Director |
|
2016-07-07 |
4 |
AS |
$73.86 |
$856,776 |
D/D |
(11,600) |
380,099 |
|
- |
|
Blin Emmanuel |
SVP, Chief Strategy Officer |
|
2016-07-02 |
4 |
D |
$73.78 |
$16,158 |
D/D |
(219) |
12,297 |
|
- |
|
Blin Emmanuel |
SVP, Chief Strategy Officer |
|
2016-07-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
951 |
12,516 |
|
- |
|
Gordon Murdo |
EVP, Chief Commercial Officer |
|
2016-07-01 |
4 |
D |
$73.78 |
$89,348 |
D/D |
(1,211) |
13,739 |
|
- |
|
Gordon Murdo |
EVP, Chief Commercial Officer |
|
2016-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,335 |
14,950 |
|
- |
|
Cuss Francis M |
EVP & CSO |
|
2016-07-01 |
4 |
D |
$73.78 |
$139,887 |
D/D |
(1,896) |
289,732 |
|
- |
|
Cuss Francis M |
EVP & CSO |
|
2016-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,655 |
291,628 |
|
- |
|
Andreotti Lamberto |
Director |
|
2016-06-30 |
4 |
A |
$73.55 |
$34,863 |
D/D |
474 |
391,699 |
|
- |
|
Andreotti Lamberto |
Director |
|
2016-06-29 |
4 |
AS |
$72.79 |
$713,342 |
D/D |
(9,800) |
392,194 |
|
- |
|
Andreotti Lamberto |
Director |
|
2016-06-28 |
4 |
AS |
$71.40 |
$960,396 |
D/D |
(13,400) |
390,394 |
|
- |
|
Elicker John E |
SVP, Public Affairs & IR |
|
2016-06-14 |
4 |
S |
$72.69 |
$859,219 |
D/D |
(11,820) |
55,011 |
|
- |
|
953 Records found
|
|
Page 25 of 39 |
|
|